ID   KMH-2
AC   CVCL_S641
SY   KMHDASH2; KMH2
DR   CLO; CLO_0037155
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03472496
DR   cancercelllines; CVCL_S641
DR   CCRID; 3101HUMSCSP551
DR   Cell_Model_Passport; SIDM00619
DR   CLS; 305142
DR   Cosmic; 2054094
DR   Cosmic-CLP; 1298167
DR   DepMap; ACH-002397
DR   EGA; EGAS00001000978
DR   GDSC; 1298167
DR   GEO; GSM827259
DR   GEO; GSM1669989
DR   JCRB; JCRB1066
DR   JCRB; NIHS0268
DR   LINCS_LDP; LCL-1684
DR   PharmacoDB; KMH2_755_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_S641
DR   Wikidata; Q54900116
RX   PubMed=11686581;
RX   PubMed=20215515;
RX   PubMed=23833040;
RX   PubMed=27397505;
RX   PubMed=30737244;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 58 hours (PubMed=11686581).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (PubMed=23833040; PubMed=30737244; DepMap).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=1.62%; Native American=0.61%; East Asian, North=81.17%; East Asian, South=14.36%; South Asian=0%; European, North=0.83%; European, South=1.41% (PubMed=30894373).
CC   Discontinued: JCRB; NIHS0268; true.
CC   Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
ST   Source(s): Cosmic-CLP; JCRB; PubMed=30737244
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 9
ST   D16S539: 9,12
ST   D18S51: 17
ST   D21S11: 30,32.2
ST   D3S1358: 15
ST   D5S818: 12,13
ST   D7S820: 11
ST   D8S1179: 13
ST   FGA: 20,22
ST   TH01: 9
ST   TPOX: 8,11
ST   vWA: 14,15
DI   NCIt; C3878; Thyroid gland anaplastic carcinoma
DI   ORDO; Orphanet_142; Anaplastic thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   71Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 05-10-23; Version: 31
//
RX   PubMed=11686581; DOI=10.1016/S0753-3322(01)00087-7;
RA   Sekiguchi M., Shiroko Y., Arai T., Kishino T., Sugawara I.,
RA   Kusakabe T., Suzuki T., Yamashita T., Obara T., Ito K., Hasumi K.;
RT   "Biological characteristics and chemosensitivity profile of four human
RT   anaplastic thyroid carcinoma cell lines.";
RL   Biomed. Pharmacother. 55:466-474(2001).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=23833040; DOI=10.1210/jc.2013-2383;
RA   Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M.,
RA   Ibrahimpasic T., Ghossein R.A., Fagin J.A.;
RT   "Frequent somatic TERT promoter mutations in thyroid cancer: higher
RT   prevalence in advanced forms of the disease.";
RL   J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953;
RA   Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C.,
RA   Copland J.A. III, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N.,
RA   Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R.,
RA   Fagin J.A., Schweppe R.E.;
RT   "Comprehensive genetic characterization of human thyroid cancer cell
RT   lines: a validated panel for preclinical studies.";
RL   Clin. Cancer Res. 25:3141-3151(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//